Literature DB >> 25285236

The Myth of Community Differences as the Cause of Variations Among IRBs.

Robert Klitzman1.   

Abstract

BACKGROUND: Although variations among institutional review boards (IRBs) have been documented for 30 years, they continue, raising crucial questions as to why they persist as well as how IRBs view and respond to these variations.
METHODS: In-depth, 2-hour interviews were conducted with 46 IRB chairs, administrators, and members. The leadership of 60 U.S. IRBs were contacted (every fourth one in the list of the top 240 institutions by NIH funding). IRB leaders from 34 of these institutions were interviewed (response rate = 55%).
RESULTS: The interviewees suggest that differences often persist because IRBs think these are legitimate, and regulations permit variations due to differing "community values." Yet, these variations frequently appear to stem more from differences in institutional and subjective personality factors, and from "more eyes" examining protocols, trying to foresee all potential future logistical problems, than from the values of the communities from which research participants are drawn. However, IRBs generally appear to defend these variations as reflecting underlying differences in community norms.
CONCLUSIONS: These data pose critical questions for policy and practice. Attitudinal changes and education among IRBs, principal investigators (PIs), policymakers, and others and research concerning these issues are needed.

Entities:  

Keywords:  attitudes; culture; ethics; policy; qualitative research; regulation; research ethics

Year:  2011        PMID: 25285236      PMCID: PMC4181844          DOI: 10.1080/21507716.2011.601284

Source DB:  PubMed          Journal:  AJOB Prim Res        ISSN: 2150-7724


  26 in total

Review 1.  Scope and impact of financial conflicts of interest in biomedical research: a systematic review.

Authors:  Justin E Bekelman; Yan Li; Cary P Gross
Journal:  JAMA       Date:  2003 Jan 22-29       Impact factor: 56.272

2.  Variation in Institutional Review processes for a multisite observational study.

Authors:  Catherine C Vick; Kelly R Finan; Catarina Kiefe; Leigh Neumayer; Mary T Hawn
Journal:  Am J Surg       Date:  2005-11       Impact factor: 2.565

Review 3.  A review finds that multicenter studies face substantial challenges but strategies exist to achieve Institutional Review Board approval.

Authors:  Sarah M Greene; Ann M Geiger
Journal:  J Clin Epidemiol       Date:  2006-03-15       Impact factor: 6.437

4.  Medical education research and IRB review: an analysis and comparison of the IRB review process at six institutions.

Authors:  Liselotte N Dyrbye; Matthew R Thomas; Alex J Mechaber; Anne Eacker; William Harper; F Stanford Massie; David V Power; Tait D Shanafelt
Journal:  Acad Med       Date:  2007-07       Impact factor: 6.893

5.  Views of the process and content of ethical reviews of HIV vaccine trials among members of US institutional review boards and South African research ethics committees.

Authors:  Robert Klitzman
Journal:  Dev World Bioeth       Date:  2008-12       Impact factor: 2.294

6.  It is time to professionalize institutional review boards.

Authors:  John Lantos
Journal:  Arch Pediatr Adolesc Med       Date:  2009-12

7.  Views and experiences of IRBs concerning research integrity.

Authors:  Robert Klitzman
Journal:  J Law Med Ethics       Date:  2011       Impact factor: 1.718

8.  Breaking the camel's back: multicenter clinical trials and local institutional review boards.

Authors:  W J Burman; R R Reves; D L Cohn; R T Schooley
Journal:  Ann Intern Med       Date:  2001-01-16       Impact factor: 25.391

9.  Problematic variation in local institutional review of a multicenter genetic epidemiology study.

Authors:  Rita McWilliams; Julie Hoover-Fong; Ada Hamosh; Suzanne Beck; Terri Beaty; Garry Cutting
Journal:  JAMA       Date:  2003-07-16       Impact factor: 56.272

10.  Variation among institutional review boards in evaluating the design of a multicenter randomized trial.

Authors:  A R Stark; J E Tyson; P L Hibberd
Journal:  J Perinatol       Date:  2009-10-01       Impact factor: 2.521

View more
  19 in total

1.  Institutional review board community members: who are they, what do they do, and whom do they represent?

Authors:  Robert Klitzman
Journal:  Acad Med       Date:  2012-07       Impact factor: 6.893

2.  Views and experiences of IRBs concerning research integrity.

Authors:  Robert Klitzman
Journal:  J Law Med Ethics       Date:  2011       Impact factor: 1.718

3.  How good does the science have to be in proposals submitted to Institutional Review Boards? An interview study of Institutional Review Board personnel.

Authors:  Robert Klitzman
Journal:  Clin Trials       Date:  2013-09-02       Impact factor: 2.486

4.  How IRB leaders view and approach challenges raised by industry-funded research.

Authors:  Robert Klitzman
Journal:  IRB       Date:  2013 May-Jun

5.  Views of IRBs Concerning their Local Ecologies: Perceptions of Relationships, Systems, and Tensions between IRBs and their Institutions.

Authors:  Robert Klitzman
Journal:  AJOB Prim Res       Date:  2013-01-01

6.  Research ethics. To protect human subjects, review what was done, not proposed.

Authors:  Robert Klitzman; Paul S Appelbaum
Journal:  Science       Date:  2012-03-30       Impact factor: 47.728

7.  Barriers to Effective Deliberation in Clinical Research Oversight.

Authors:  Danielle M Wenner
Journal:  HEC Forum       Date:  2016-09

8.  How IRBs view and make decisions about consent forms.

Authors:  Robert L Klitzman
Journal:  J Empir Res Hum Res Ethics       Date:  2013-02       Impact factor: 1.742

9.  How US institutional review boards decide when researchers need to translate studies.

Authors:  Robert Klitzman
Journal:  J Med Ethics       Date:  2013-03-08       Impact factor: 2.903

10.  How IRBs view and make decisions about coercion and undue influence.

Authors:  Robert Klitzman
Journal:  J Med Ethics       Date:  2012-09-14       Impact factor: 2.903

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.